Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 28.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.48M |
| Shares Out | 13.65M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $1.99 |
| Previous Close | $1.99 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.00 |
| Day's Range | 1.98 - 2.04 |
| Day's Volume | 149,448 |
| 52-Week Range | 1.05 - 3.03 |
News
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the dev...
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for ...
ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021 CHARLOTTESVILLE, VA / ACCESSWIRE / December 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage bio...
About ADIL
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.
| Industry Biotechnology | IPO Date Jul 30, 2018 |
| CEO William B. Stilley III, M.B.A., MBA | Employees 3 |
| Stock Exchange NASDAQ | Ticker Symbol ADIL |